# Genpact Limited (G) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Technology / IT Services. Price $37.32, market value $6.3 billion.

## Valuation
- **P/E (trailing): 11.1×** (5-yr avg 17.8×, 3-yr avg 13.1×). Genpact Limited trades at 11.1× trailing earnings, well below its own five-year average of 17.8×: cheap by its own standards. The Technology median in the September 2026 study was 32.1×. Forward P/E is 8.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.84**. A PEG of 0.84 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.2×**. Each dollar of revenue is priced at 1.2×.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 9.1%** (5-yr avg 6.9%). Free cash flow equals 9.1% of the market value, above its five-year average of 6.9%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 9.0%**. The inverse of the P/E: 9.0% of the price is earned each year.

## Profitability
- **Gross margin: 36.5%**. Genpact Limited keeps 36.5% of revenue after the direct cost of what it sells.
- **Operating margin: 14.8%**. 14.8% of revenue is left after running the business.
- **Net margin: 10.9%**. 10.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 21.7%**. 21.7% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 19.0%**. Return on all capital, debt included, is 19.0%: comfortably above what that capital costs.
- **Return on assets: 10.0%**. Each dollar of assets produces 10.0% of profit.

## Growth
- **Revenue growth (1 yr): 6.6%** (3-yr 5.1%/yr, 5-yr 6.5%/yr). Revenue grew 6.6% over the last year, against 6.5% a year compounded over five years.
- **EPS growth (1 yr): 9.8%** (3-yr 18.5%/yr, 5-yr 14.8%/yr). Earnings per share rose 9.8%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 23.2%/yr**. Free cash flow has compounded at 23.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.60**. Debt is 0.60 times equity, moderate leverage.
- **Altman Z-score: 3.05**. A Z-score of 3.05 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.01%** ($0.71 per share, trailing). Genpact Limited yields 2.01%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 21%** (21% of free cash flow). 21% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 9**. 9 straight years of increases.
- **Dividend growth (5 yr): 11.6%/yr** (1-yr 11.1%). The dividend has compounded at 11.6% a year over five years, doubling roughly every 6 years at that pace.

## Price and momentum
- **Total return (1 yr): -15.8%** (YTD -19.4%, 3-mo 15.1%). The shares are down 15.8% over twelve months including dividends.
- **From 52-week high: -23.3%** (39.0% above the low). Trading 23% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.18** (volatility 38%). Beta of 0.18 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=G · Page: https://foliofundamentals.com/stocks/g

Not investment advice.